Cantor Fitzgerald Weighs in on Legend Biotech FY2026 Earnings

Legend Biotech Co. (NASDAQ:LEGN) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Legend Biotech in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings per share of $0.24 for the year. Cantor Fitzgerald has a “Overweight” rating and a $55.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.33. The business had revenue of $195.05 million during the quarter, compared to analysts’ expectations of $190.83 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm’s revenue for the quarter was up 107.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.16) EPS.

Several other equities analysts also recently commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $84.00 price target on shares of Legend Biotech in a research note on Tuesday, April 22nd. Morgan Stanley cut their price objective on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, March 17th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Legend Biotech in a report on Wednesday, April 16th. Truist Financial dropped their price target on shares of Legend Biotech from $88.00 to $71.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Finally, Guggenheim reissued a “neutral” rating on shares of Legend Biotech in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Legend Biotech presently has an average rating of “Moderate Buy” and an average price target of $76.20.

Legend Biotech Stock Down 0.6%

LEGN stock opened at $34.78 on Tuesday. Legend Biotech has a fifty-two week low of $27.34 and a fifty-two week high of $60.87. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of -36.61 and a beta of 0.13. The business’s fifty day moving average price is $31.50 and its two-hundred day moving average price is $34.53.

Institutional Trading of Legend Biotech

Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. lifted its stake in Legend Biotech by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,092 shares of the company’s stock worth $71,000 after purchasing an additional 377 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Legend Biotech by 1.4% during the 1st quarter. Rhumbline Advisers now owns 28,029 shares of the company’s stock worth $951,000 after buying an additional 391 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Legend Biotech by 1.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,610 shares of the company’s stock worth $1,887,000 after buying an additional 579 shares during the last quarter. GAMMA Investing LLC boosted its stake in Legend Biotech by 145.4% in the first quarter. GAMMA Investing LLC now owns 1,291 shares of the company’s stock valued at $44,000 after buying an additional 765 shares in the last quarter. Finally, Shell Asset Management Co. boosted its stake in Legend Biotech by 62.0% in the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company’s stock valued at $68,000 after buying an additional 800 shares in the last quarter. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).